Amyloid Neuropathies, Familial: all 188 studies

Page 2 of 2. Open to participants first (94), then studies with results posted, then the rest; newest registration first within each.

• Cardiac Uptake of 18F Florbetapir in Patients Undergoing ChemotherapyTerminatedNCT03333551Phase 4Results posted
• The Role of F-18 Florbetapir in the Early Detection of Cardiac AmyloidosisTerminatedNCT03040427Phase 4Results posted
• Long-term Safety of Tafamidis in Subjects With Transthyretin CardiomyopathyCompletedNCT02791230Phase 3Results posted
• The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver TransplantCompletedNCT02595983Phase 2Results posted
• The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)CompletedNCT02510261Phase 3Results posted
• ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)CompletedNCT02319005Phase 3Results posted
• Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)CompletedNCT02175004Phase 3Results posted
• Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)CompletedNCT02146378Results posted
• Safety and Efficacy of Tafamidis in Patients With Transthyretin CardiomyopathyCompletedNCT01994889Phase 3Results posted
• APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated AmyloidosisCompletedNCT01960348Phase 3Results posted
• Doxycycline and TUDCA in Patients With Transthyretin Amyloid CardiomyopathyCompletedNCT01855360Phase 1/2Results posted
• Efficacy and Safety of Inotersen in Familial Amyloid PolyneuropathyCompletedNCT01737398Phase 2/3Results posted
• Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission TomographyCompletedNCT01683825Phase 4Results posted
• Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And CaregiversCompletedNCT01604122Results posted
• The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M TransthyretinCompletedNCT01435655Phase 3Results posted
• An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid PolyneuropathyCompletedNCT00791492Phase 2/3Results posted
• Safety and Efficacy Study of Fx-1006A in Patients With Familial AmyloidosisCompletedNCT00409175Phase 2/3Results posted
• The Effect of Diflunisal on Familial AmyloidosisCompletedNCT00294671Phase 2/3Results posted
• Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac AmyloidosisCompletedNCT07605741
• EFICAC-TTR Trial: Exercise and Nutritional Supplementation in Transthyretin Cardiac AmyloidosisCompletedNCT07343999Not applicable
• An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.Active, not recruitingNCT07062848
• Test-retest Study With [18F]FBB in Cardiac AmyloidosisCompletedNCT06790394Phase 1
• REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosisCompletedNCT06788535Phase 3
• A Phase 3 Study of NTLA-2001 in ATTRv-PNActive, not recruitingNCT06672237Phase 3
• hATTR Polyneuropathy in RussiaCompletedNCT06365593
• Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid CardiomyopathyCompletedNCT06261216
• Cardiac Amyloidosis in HFpEF Tunisian PatientsCompletedNCT06201832
• Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid CardiomyopathyCompletedNCT05795400Not applicable
• The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based MetabolomicsStatus unknownNCT05718401
• Prevalence of Cardiac Amyloidosis Among Patients With a History of Lumbar Spinal Stenosis.Status unknownNCT05701410Not applicable
• Prevalence of Cardiac Amyloidosis in Patients Undergoing Surgery for Lumbar Spinal Stenosis.Status unknownNCT05701397Not applicable
• Screening Algorithm for Early Detection of Occult Cardiac AmyloidosisCompletedNCT05693376
• Molecular Imaging of Myocardial Fibrosis in Cardiac AmyloidosisActive, not recruitingNCT05619302Phase 3
• Artificial Intelligence Enhanced ECG to Detect Cardiac AmyloidosisCompletedNCT05557162Not applicable
• Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain AmyloidosisActive, not recruitingNCT05452850
• Left Atrial Strain and Supraventricular Arrhythmia Burden in Cardiac Light Chain Amyloidosis Following ChemotherapyActive, not recruitingNCT05448716
• Intracardiac Flow Assessment in Cardiac AmyloidosisCompletedNCT05379101
• Early Detection of Neuropathy in ATTRvCompletedNCT05311488
• Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisCompletedNCT05184088Phase 3
• Cardiac Contractility Modulation Therapy in Amyloid Cardiomyopathy Patients With Heart FailureStatus unknownNCT05167799
• Amyloidosis TTR Flow Reserve EvaluationActive, not recruitingNCT05103943Not applicable
• Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran TherapyCompletedNCT05023889Early Phase 1
• N-of-1 for Beta-Blockers in Cardiac AmyloidosisCompletedNCT05019027Phase 4
• Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsActive, not recruitingNCT04988386Phase 3
• Exercise Effect on Transthyretin StabilityStatus unknownNCT04986826
• Increasing Amyloidosis Awareness and Diagnosis Through Programmatic Imaging, Blood/Urine Testing and PathologyStatus unknownNCT04983433
• High Resolution Three-dimensional Maps of the Right Chambers in Patient Diagnosed With Cardiac AmyloidosisStatus unknownNCT04956965Not applicable
• Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)WithdrawnNCT04882735Phase 3
• Screening for Amyloidosis Before Aortic Valve Elective ReplacementActive, not recruitingNCT04869631
• CMR T1 Mapping for Diagnosis of Cardiac AmyloidosisCompletedNCT04862273
• Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop RecordersCompletedNCT04856267
• Unmasking the Prevalence of AC in an Unselected Echocardiographic PopulationStatus unknownNCT04738266
• Study of Olfactory Disorders in Patients With Cardiac AmyloidosisCompletedNCT04661800Not applicable
• Cardiac Amyloidosis in Spinal Stenosis: the CASS-studyActive, not recruitingNCT04653675
• Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release SurgeryTerminatedNCT04611204
• Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)CompletedNCT04601051Phase 1
• Cardiac Amyloidosis : Diagnostic Using Red Flag SignalsStatus unknownNCT04459169
• Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid PolyneurophathyWithdrawnNCT04418024Phase 3
• Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac AmyloidosisStatus unknownNCT04387344
• Targeted Testing for ATTR Among Aortic Stenosis Patients-PilotWithdrawnNCT04363294Not applicable
• Frontline Lenalidomide for AL Amyloidosis Involving MyocardiumCompletedNCT04298372Phase 3
• A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A MutationCompletedNCT04201418
• The Potential Role of 18F-NaF PET/CT in Diagnosing Cardiac AmyloidosisStatus unknownNCT04146480Not applicable
• Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT CameraStatus unknownNCT04146415Not applicable
• Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CTTerminatedNCT04105634Early Phase 1
• ATTR Amyloidosis in Elderly Patients With Aortic StenosisStatus unknownNCT04061213
• Prevalence of Wild Type Transthyretin Cardiac Amyloidosis in Patients Operated for Idiopathic Carpal Tunnel SyndromeCompletedNCT03996382Not applicable
• Impact of Amyloidosis on TAVI PatientsStatus unknownNCT03984877
• Early and Systematic Screening in Chronic NeuropathyCompletedNCT03720275Not applicable
• PET/MR Imaging In Patients With Cardiac AmyloidosisCompletedNCT03626584
• Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid DepositsCompletedNCT03616496Not applicable
• Monitoring of Early Disease Progression in Hereditary Transthyretin AmyloidosisCompletedNCT03431896
• Mitochondrial Function in Transthyretin AmyloidosisTerminatedNCT03328338
• Frequency of Cardiac Amyloidosis in the Caribbean's. (TEAM Amylose)CompletedNCT03322319Not applicable
• Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10CompletedNCT03294707Phase 1
• TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive SubjectsCompletedNCT03237494
• Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.TerminatedNCT03232632Early Phase 1
• Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown AetiologyCompletedNCT03190577Not applicable
• PET/MRI Evaluation of Cardiac AmyloidCompletedNCT03119558Early Phase 1
• The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.CompletedNCT03029026
• Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac AmyloidosisStatus unknownNCT02966522Phase 2
• Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)Approved for marketingNCT02939820
• A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy SubjectsCompletedNCT02797847Phase 1
• Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)WithdrawnNCT02713880
• Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance ImagingWithdrawnNCT02462213
• Study of SOM0226 in Familial Amyloid PolyneuropathyCompletedNCT02191826Phase 1/2
• Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)CompletedNCT01705626
• Prevalence of Transthyretin Amyloidosis in Hypertrophic CardiomyopathyCompletedNCT01623245

← Amyloid Neuropathies, Familial overview